Abstract
Background Deep brain stimulation (DBS) of the ventral internal capsule/ventral striatum (VCVS) is an emerging treatment for obsessive-compulsive disorder (OCD). Recently, multiple studies using normative connectomes have correlated DBS outcomes to stimulation of specific white matter tracts. Those studies did not test whether these correlations are clinically predictive, and did not apply cross-validation approaches that are necessary for biomarker development. Further, they did not account for the possibility of systematic differences between DBS patients and the non-diagnosed controls used in normative connectomes.
Methods We performed patient-specific diffusion imaging in 8 patients who underwent VCVS DBS for OCD. We delineated tracts connecting thalamus and subthalamic nucleus (STN) to prefrontal cortex via VCVS. We then calculated which tracts were likely activated by individual patients’ DBS settings. We fit multiple statistical models to predict both OCD and depression outcomes from tract activation. We further attempted to predict hypomania, a VCVS DBS complication. We assessed all models’ performance on held-out test sets.
Results No model predicted OCD response, depression response, or hypomania above chance. Coefficient inspection partly supported prior reports, in that capture of tracts projecting to cingulate cortex was associated with both YBOCS and MADRS response. In contrast to prior reports, however, tracts connected to STN were not reliably correlated with response.
Conclusions Patient-specific imaging and a guideline-adherent analysis were unable to identify a tractographic target with sufficient effect size to drive clinical decision-making or predict individual outcomes. These findings suggest caution in interpreting the results of normative connectome studies.
Competing Interest Statement
ASW and DDD have received research funding, device donations, and honoraria from Medtronic, which manufactured the DBS devices used in patients' clinical care. Medtronic had no financial or technical role in this study. ASW and CCM have multiple patents and patent filings in the area of deep brain stimulation, including methods for optimizing/customizing stimulation parameters. CCM is a paid consultant for Boston Scientific Neuromodulation, receives royalties from Hologram Consultants, Neuros Medical, Qr8 Health, and is a shareholder in the following companies: Hologram Consultants, Surgical Information Sciences, CereGate, Autonomic Technologies, Cardionomic, and Enspire DBS. All other authors affirm no related financial interests.
Clinical Trial
not a prospective trial; retrospective analysis
Funding Statement
This work was supported by NIH grants R03MH111320 (ASW, CCM, DDD), UH3NS100548 (ASW, DDD), R01MH111917 (ASW, DDD, NMM, YR), U01U01MH076179 (BDG), P20GM130452 (NCM, BDG), K23MH100607 (NCM), and P50MH106435 (NCM, BDG). ASW further acknowledges support from the MnDRIVE Brain Conditions and Minnesota Medical Discovery Team - Addictions initiatives. All opinions and conclusions herein are those of the authors. They do not represent the views or official policy of any public or private funding body.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Institutional Review Boards of Massachusetts General Hospital and Butler Hospital approved the protocols and provided ethical oversight.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
De-identified data tables and analysis code used to produce all exhibits in this manuscript will be available at the time of journal publication at https://github.com/tne-lab.
